Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial ; volume:30 ; number:1 ; day:5 ; month:12 ; year:2023 ; pages:271-278 ; date:1.2024
Nature medicine ; 30, Heft 1 (5.12.2023), 271-278, 1.2024
- Urheber
-
Desai, Jayesh
Alonso, Guzman
Kim, Se Hyun
Cervantes, Andres
Karasic, Thomas
Medina, Laura
Shacham-Shmueli, Einat
Cosman, Rasha
Falcon, Alejandro
Gort, Eelke
Guren, Tormod
Massarelli, Erminia
Miller, Wilson H.
Paz-Ares, Luis
Prenen, Hans
Amatu, Alessio
Cremolini, Chiara
Kim, Tae Won
Moreno, Victor
Ou, Sai-Hong
Passardi, Alessandro
Sacher, Adrian
Santoro, Armando
Stec, Rafal
Ulahannan, Susanna
Arbour, Kathryn
Lorusso, Patricia
Luo, Jia
Patel, Manish R.
Choi, Yoonha
Shi, Zhen
Mandlekar, Sandhya
Lin, Mark T.
Royer-Joo, Stephanie
Chang, Julie
Jun, Tomi
Dharia, Neekesh V.
Schutzman, Jennifer L.
Han, Sae-Won
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41591-023-02696-8
- URN
-
urn:nbn:de:101:1-2024040122330805854412
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Desai, Jayesh
- Alonso, Guzman
- Kim, Se Hyun
- Cervantes, Andres
- Karasic, Thomas
- Medina, Laura
- Shacham-Shmueli, Einat
- Cosman, Rasha
- Falcon, Alejandro
- Gort, Eelke
- Guren, Tormod
- Massarelli, Erminia
- Miller, Wilson H.
- Paz-Ares, Luis
- Prenen, Hans
- Amatu, Alessio
- Cremolini, Chiara
- Kim, Tae Won
- Moreno, Victor
- Ou, Sai-Hong
- Passardi, Alessandro
- Sacher, Adrian
- Santoro, Armando
- Stec, Rafal
- Ulahannan, Susanna
- Arbour, Kathryn
- Lorusso, Patricia
- Luo, Jia
- Patel, Manish R.
- Choi, Yoonha
- Shi, Zhen
- Mandlekar, Sandhya
- Lin, Mark T.
- Royer-Joo, Stephanie
- Chang, Julie
- Jun, Tomi
- Dharia, Neekesh V.
- Schutzman, Jennifer L.
- Han, Sae-Won
- SpringerLink (Online service)
Ähnliche Objekte (12)
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Lasting response by vertical inhibition with cetuximab and trametinib in \(\it KRAS\)-mutated colorectal cancer patient-derived xenografts
Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab
Colorectal cancer with KRAS mutation
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab
Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Lasting response by vertical inhibition with cetuximab and trametinib in \(\it KRAS\)-mutated colorectal cancer patient-derived xenografts
Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab
Colorectal cancer with KRAS mutation
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab
Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Lasting response by vertical inhibition with cetuximab and trametinib in \(\it KRAS\)-mutated colorectal cancer patient-derived xenografts
Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab
Colorectal cancer with KRAS mutation
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab